Compare Incyte Corporation (INCY) vs Mattel Inc (MAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Mattel Inc — how do they compare? Incyte Corporation trades at $121.06 (market cap $24.54B), while Mattel Inc trades at $15.05 (market cap $4.30B). The key difference: Incyte Corporation is far larger — about 5.7× Mattel Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Mattel Inc nearer its low. Which is the better fit depends on your goals.
| INCY | MAT | |
|---|---|---|
Market Cap | $24.54B | $4.30B |
Sector | Health | Consumer Cyclical |
52-Week High | $129.93 | $22.16 |
52-Week Low | $81.61 | $13.05 |
Enterprise Value | $20.04B | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Mattel (MAT) trades at $14.76, up 0.14%, with a bullish technical signal from moving averages. The company reported mixed Q2 2026 results with a 10% revenue beat but an earnings miss, reflecting margin pressure from higher costs. Valuation appears reasonable with a P/E of 11.22 and P/S of 0.84, while profitability metrics like a 7.78% net margin and 20.5% ROE remain solid. Recent news highlights growth from toy-based films and adult collectors, though competitive and cost challenges persist.
The outlook is cautiously optimistic, supported by brand strength and entertainment initiatives, but near-term earnings volatility and discretionary spending sensitivity pose risks. Analyst consensus leans Buy with a $14.00 price target, suggesting modest upside potential from current levels amid ongoing execution scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Mattel Inc
Mattel markets toy products that are sold to its wholesale customers and direct to retail consumers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, handheld and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas & Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Just over half of its net sales are in North America, while the remainder stem from international markets.
Read more on MAT →
